RxDoctor Payments Data

Kenneth Zabel, MD

Cardiovascular Disease · Lawrence, KSNPI 1841248267

Payments from drug & device makers

$908in general payments, 2019–2025

Across 41 payments — averaging $22.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$244
  • E.r. Squibb & Sons, L.L.C.$157
  • Novartis$124
  • Amgen$114
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$87
  • Boston Scientific$48
  • plus $134 from 5 others

What the payments were for

  • Food & beverage$908100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$908 in reported general payments places this provider in the 25th percentile of 175 cardiovascular disease providers in Kansas.

See all cardiovascular disease providers in Kansas

Medicare billing

Part B allowed, 2024
$423,725
Medicare patients
3,349
Services billed
19,902

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban595$514,853
XareltoRivaroxaban164$173,032
Repatha SureclickEvolocumab79$62,123
EntrestoSacubitril/Valsartan63$53,835
Praluent PenAlirocumab45$25,070
Repatha SyringeEvolocumab11$12,675
BrilintaTicagrelor18$9,246
Dabigatran EtexilateDabigatran Etexilate Mesylate11$4,099
Diltiazem 24hr Er (Cd)Diltiazem Hcl151$3,580
Metoprolol Succinate312$3,061
Atorvastatin Calcium339$2,157
Flecainide Acetate92$2,034
Losartan Potassium287$2,014
Carvedilol324$1,891
Ezetimibe116$1,703

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$35$514,853595 claims
NovartisEntresto$124$53,83563 claims
AstraZenecaBrilinta$16$9,24618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 175 cardiovascular disease providers in Kansas.

Other cardiovascular disease in Lawrence

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →